Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration

Sponsor
Università degli Studi di Brescia
Study ID
NCT02060604
Phase
PHASE4
Status
Completed

Conditions

  • Wet Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The addition of an anti-inflammatory agent could be a valid option for controlling choroidal neovascularization, as simply inhibiting VEGF addresses neither the multifactorial pathogenesis of choroidal neovascularization nor the underlying cause of VEGF production.

Key Dates

First listed
Feb 12, 2014
Start date
Dec 31, 2012
Status verified
Feb 2014
Primary completion
Jan 31, 2014
Completion
Jan 31, 2014

Study Design

Enrollment
60 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Ketorolac + Ranibizumab
    3 monthly ranibizumab, then as needed plus ketorolac eyedrops TID
  • Active Comparator: Ranibizumab Alone
    3 monthly ranibizumab, then as needed

Primary Outcome Measure

mean change in study eye visual acuity as measured by the best-corrected ETDRS letter score [ Time Frame: 12 months ]

Related Studies